clinical trial · NCT07284745
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
Bristol-Myers Squibb·phase3·not yet recruiting·n = 176
Irritability Associated With Autism Spectrum DisorderKarXTKarX-ECKarXT + KarX-EC Matching Placebo
brief summary
The purpose of this study is to assess KarXT + KarX-EC for the treatment of irritability associated with autism in children and adolescents.
started
Sep 11, 2026
primary completion
Jul 5, 2029
completion
Jul 5, 2029
last updated
Apr 2, 2026
official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of KarXT + KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol